-
-
-
This is the latest of several important publications by Dr. Fullerton and her colleagues, at The University of California at San Francisco, describing details of the epidemiology of pediatric stroke during the last 2 decades of the 20th century.
-
These papers and the accompanying editorial by Rascol bring attention to a known but under-recognized complication of ergot derivatives.
-
Treatment of TGA patients with antiplatelet treatment is likely warranted, particularly if there are underlying vascular risk factors.
-
Converging evidence implicates both protein aggregation as well as oxidative damage in mitochondrial dysfunction in Parkinsons disease pathogenesis. It is likely that these factors may interact.
-
These findings are amongst the most direct data to date that oxidative damage plays a critical role in normal human aging.
-
The good news from the Oxford Vascular Study is that community-wide risk factor modifications and preventive treatment are worth the effort, and that further reductions in stroke incidence are possible with more widespread stroke prevention programs.
-
In late-onset VAP, survival improved and costs decreased using initial coverage with 3 antibiotics. Mini-BAL did not improve survival, but decreased costs and antibiotic usage.
-
This concise review makes a compelling case for a change in the healthcare workers behavior. Helpful hints including increasing the use of alcohol-based formulations to reduce the time constrains are provided throughout the article.